Active Share (vs S&P 500): 100.0%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-13.6%
· vs SPY
-15.8%
· Prev Value $11.51B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-1.6%
· vs SPY
-3.7%
· Latest Value $9.72B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 88 equity positions with a combined reported value of $9.72B. The filing implies a focused portfolio: its ten largest positions account for 62.7% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were ASND ($2.34B), PBLS ($942.16M), PCVX ($652.90M). By sector, the heaviest allocations are Health Care 99.3%, Financials 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+1.3pp) and away from Other (-1.2pp).
Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 74% of names.
The largest new positions opened in Q3 2026 were AMLX ($124.53M), VRDN ($81.79M), DBVT ($43.01M).
Of the 11 positions fully exited versus the prior quarter, the largest were BCRX ($158.27M), NUVL ($153.94M), NTLA ($76.60M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.
Investment Approach
Focuses on healthcare sector investments
Long-term, value-oriented strategy
Deep fundamental research and analysis
Asset Classes & Strategy
Primarily invests in public equities
Also manages private investments in healthcare companies
Concentrated portfolio approach with significant positions in healthcare companies
Key Personnel
Peter Kiernan: Founder and portfolio manager
Team of experienced investment professionals with healthcare expertise
Notable Facts
Founded in 2002
Manages approximately $16.4 billion in assets
Files SEC Form 13F for US equity positions
This profile is based on publicly available information and should not be considered as official disclosure from the firm.
AI Rebalance Analysis
1. Overall direction and market view: The fund increased its total portfolio value by $9716.0M, with a clear focus on adding positions in biotech/healthcare (PBLS, ARTV) while selectively reducing others (SEPN), suggesting a bullish stance on innovative therapeutics but with some profit-taking.
2. Key moves:
- Added: PBLS (Parabilis Medicines, +2.82% weight), ARTV (Artiva Biotherapeutics, +0.76% weight).
- Reduced: SEPT (Septerna, -21.3% shares sold, weight unchanged due to price effect).
3. Portfolio structure: Highly active, concentrated in Health Care (100% of top 10), with a preference for clinical-stage biotech/pharma, indicating high-risk, high-reward appetite.
4. Per-holding one-liner:
- ASND: Ascendis Pharma (growth hormone disorders).
- PBLS: Parabilis Medicines (unverified, likely biotech).
- PCVX: Vaxcyte (vaccine development).
- RYTM: Rhythm Pharmaceuticals (obesity/rare diseases).
- EWTX: Edgewise Therapeutics (muscle disorders).
- TYRA: Tyra Biosciences (unverified, likely oncology).
- COAG: Hemab Therapeutics (hemophilia).
- NAMS: NewAmsterdam Pharma (metabolic diseases).
- ARTV: Artiva Biotherapeutics (unverified, likely immuno-oncology).
- SEPN: Septerna (GI disorders).
5. Style summary: Aggressive biotech investor doubling down on high-potential clinical-stage names while trimming losers.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:28
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q2)
P 70%R 70%F1 70%(modelled on 2026-Q1; 7/10 hit)
Low-confidence forecast
This fund replaces about 26% of its Top-10 each quarter and
backtests at F1 73% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return-17.38%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return-0.37%vs benchmark
Barra annualised vol61.1%Model estimate
Realised vol60.6%Annualised in window
Weighted beta1.24Raw exposure
Factor / specific risk38% / 62%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
-17.38%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
-0.37%
Portfolio − benchmark
Arithmetic return sum
-16.64%
Difference vs compounded is the cross term
Weighted raw beta
1.24
Weighted holding betas
Realised volatility (annualised)
60.62%
Daily returns in window
Barra model volatility (annualised)
61.13%
Factor + specific
Factor share of variance
37.6%
Barra factors
Specific share of variance
62.4%
Stock residuals
Reported value
$398.8M
13F long US equity
2. Return attribution
The -16.64% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
-7.85%
-47.2%
Momentum & Growth
3
-3.88%
-23.3%
Volatility & Tail Risk
7
+13.82%
83.0%
Industry
12
+6.98%
42.0%
Specific
1
-25.70%
-154.5%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Kurtosis
Style
+1.86
+7.51%
+13.97%
83.9%
Skewness
Style
-1.98
-4.39%
+8.72%
52.4%
Residual Volatility
Style
+2.32
+3.29%
+7.63%
45.9%
Health Care
Industry
+1.00
+6.98%
+6.98%
42.0%
Size
Style
-1.66
-1.95%
+3.23%
19.4%
Non-linear Size
Style
+3.07
+1.01%
+3.10%
18.6%
Beta
Style
+0.38
+4.44%
+1.70%
10.2%
Max Drawdown
Style
-0.68
-1.76%
+1.20%
7.2%
Short-term Reversal
Style
+0.62
+0.87%
+0.54%
3.3%
Liquidity
Style
+0.81
+0.36%
+0.29%
1.8%
Amihud Illiquidity
Style
+2.75
-0.45%
-1.23%
-7.4%
Momentum
Style
+0.48
-4.00%
-1.93%
-11.6%
Growth
Style
-1.43
+1.75%
-2.49%
-15.0%
Leverage (Downside Vol)
Style
+2.61
-1.71%
-4.48%
-26.9%
Mid Cap
Style
+2.67
-1.94%
-5.17%
-31.1%
Turnover
Style
+1.68
-4.80%
-8.08%
-48.6%
Historical Volatility
Style
+1.07
-14.00%
-14.92%
-89.6%
Specific
Specific
—
—
-25.70%
-154.5%
3. Risk attribution
Annualised volatility is 61.13%; factor risk explains 37.6% of variance and specific risk 62.4%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
62.5%
+38.17%
38.2%
Mid Cap
Style
+2.67
6.8%
+4.13%
4.1%
Health Care
Industry
+1.00
6.6%
+4.01%
4.0%
Leverage (Downside Vol)
Style
+2.61
5.9%
+3.63%
3.6%
Residual Volatility
Style
+2.32
5.1%
+3.14%
3.1%
Historical Volatility
Style
+1.07
4.1%
+2.53%
2.5%
Size
Style
-1.66
3.0%
+1.81%
1.8%
Non-linear Size
Style
+3.07
2.6%
+1.57%
1.6%
Amihud Illiquidity
Style
+2.75
1.9%
+1.16%
1.2%
Beta
Style
+0.38
1.3%
+0.77%
0.8%
Growth
Style
-1.43
1.3%
+0.77%
0.8%
Turnover
Style
+1.68
1.1%
+0.69%
0.7%
Liquidity
Style
+0.81
1.0%
+0.62%
0.6%
Momentum
Style
+0.48
0.2%
+0.12%
0.1%
Kurtosis
Style
+1.86
-0.5%
-0.31%
-0.3%
Max Drawdown
Style
-0.68
-0.5%
-0.31%
-0.3%
Short-term Reversal
Style
+0.62
-0.8%
-0.50%
-0.5%
Skewness
Style
-1.98
-1.5%
-0.89%
-0.9%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-1.66
+2.10
-3.76
Non-linear Size
+3.07
+1.68
+1.39
Mid Cap
+2.67
+0.13
+2.54
Beta
+0.38
+1.29
-0.91
Momentum
+0.48
+0.72
-0.23
Short-term Reversal
+0.62
-0.64
+1.26
Residual Volatility
+2.32
-0.40
+2.72
Historical Volatility
+1.07
+0.86
+0.21
Liquidity
+0.81
+0.11
+0.70
Amihud Illiquidity
+2.75
+1.16
+1.60
Turnover
+1.68
+0.21
+1.48
Growth
-1.43
+0.58
-2.01
Leverage (Downside Vol)
+2.61
+0.14
+2.47
Skewness
-1.98
+0.24
-2.22
Kurtosis
+1.86
+0.21
+1.65
Max Drawdown
-0.68
-0.08
-0.60
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Consumer Staples
0.0%
0.8%
+0.00%
+15.26%
-0.27%
-0.13%
+0.13%
-0.13%
Consumer Discretionary
0.0%
8.8%
+0.00%
+3.76%
-1.84%
-0.33%
+0.33%
-0.33%
Industrials
0.0%
11.1%
+0.00%
+4.36%
-2.39%
-0.48%
+0.48%
-0.48%
Health Care
100.0%
1.7%
-17.75%
+8.29%
+24.98%
-0.45%
-25.59%
-17.89%
Total
+23.98%
+15.39%
-41.43%
-2.05%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
NAMS
NEWAMSTERDAM PHARMA COMPANY
Health Care
58.24%
-19.98%
-11.64%
Hold
TSHA
TAYSHA GENE THERAPIES INC
Health Care
37.16%
-16.63%
-6.18%
Add
SGMT
SAGIMET BIOSCIENCES INC
Health Care
4.46%
+2.53%
+0.11%
New
PTN
PALATIN TECHNOLOGIES INC
Health Care
0.14%
-30.95%
-0.04%
Hold
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
SGMT
Health Care
4.46%
+2.53%
+0.11%
2
PTN
Health Care
0.14%
-30.95%
-0.04%
3
TSHA
Health Care
37.16%
-16.63%
-6.18%
4
NAMS
Health Care
58.24%
-19.98%
-11.64%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -17.38%, versus -17.01% for the QQQ synthetic benchmark — an excess of -0.37%.
Return attribution: the largest positive style/industry contributions came from Kurtosis +13.97%, Skewness +8.72%, Residual Volatility +7.63%; the largest drags came from Historical Volatility -14.92%, Turnover -8.08%, Mid Cap -5.17%. Specific (stock-level) return contributed -25.70%.
Risk attribution: Barra model volatility is 61.13% annualised; factor risk explains 38% of variance and specific risk 62%. The largest factor risk sources are Mid Cap 6.8%, Health Care 6.6%, Leverage (Downside Vol) 5.9%.
Style tilt: size -1.66, momentum +0.48, volatility +1.07, liquidity +0.81; the weighted raw beta is 1.24. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.39% and interaction -41.43%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did RA CAPITAL MANAGEMENT, L.P. buy in 2026-Q3?
In its 2026-Q3 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 88 equity positions worth $9.72B in aggregate; its largest disclosed positions were ASND ($2.34B), PBLS ($942.16M), PCVX ($652.90M).
How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?
RA CAPITAL MANAGEMENT, L.P. reported $9.72B of long equity holdings across 88 positions as of 2026-Q3. Top-10 holdings account for 62.7% of reported value.
What is RA CAPITAL MANAGEMENT, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/ra-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>